TNGX - Tango Therapeutics, Inc. Stock Price, Fair Value and News

7.44USD+0.11 (+1.50%)Market Closed

Market Summary

USD7.44+0.11

Market Closed

1.50%

TNGX Stock Price

View Fullscreen

TNGX RSI Chart

TNGX Valuation

Market Cap

794.0M

Price/Earnings (Trailing)

-7.8

Price/Sales (Trailing)

21.74

EV/EBITDA

-7.78

Price/Free Cashflow

-6.64

TNGX Price/Sales (Trailing)

TNGX Profitability

EBT Margin

-280.92%

Return on Equity

-40.2%

Return on Assets

-25.27%

Free Cashflow Yield

-15.05%

TNGX Fundamentals

TNGX Revenue

Revenue (TTM)

36.5M

Rev. Growth (Yr)

-15.29%

Rev. Growth (Qtr)

-49.39%

TNGX Earnings

Earnings (TTM)

-101.7M

Earnings Growth (Yr)

-5.86%

Earnings Growth (Qtr)

-38.18%

Breaking Down TNGX Revenue

Last 7 days

1.8%

Last 30 days

-3.4%

Last 90 days

-35.5%

Trailing 12 Months

116.9%

How does TNGX drawdown profile look like?

TNGX Financial Health

Current Ratio

7.54

TNGX Investor Care

Shares Dilution (1Y)

15.90%

Diluted EPS (TTM)

-1.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	24.9M	33.7M	37.5M	36.5M
2022	36.4M	24.0M	24.2M	24.9M
2021	18.8M	29.9M	31.6M	37.0M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Tango Therapeutics, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 20, 2024	third rock ventures iv, l.p.	sold	-1,950,000	12.00	-162,500	-
Feb 07, 2024	barry douglas	sold	-17,087	12.6198	-1,354	general counsel
Feb 07, 2024	crystal adam	sold	-51,526	12.6198	-4,083	see remarks
Feb 07, 2024	weber barbara	sold	-56,246	12.6198	-4,457	chief executive officer
Feb 07, 2024	beckman daniella	sold	-22,930	12.6198	-1,817	chief financial officer
Feb 06, 2024	barry douglas	sold	-17,864	12.5626	-1,422	general counsel
Feb 06, 2024	crystal adam	sold	-53,868	12.5626	-4,288	see remarks
Feb 06, 2024	weber barbara	sold	-58,805	12.5626	-4,681	chief executive officer
Feb 06, 2024	beckman daniella	sold	-23,969	12.5626	-1,908	chief financial officer
Feb 01, 2024	barry douglas	acquired	-	-	22,859	general counsel

Which funds bought or sold TNGX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Zurcher Kantonalbank (Zurich Cantonalbank)	reduced	-0.18	-27,447	110,183	-%
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-10.44	-393,159	1,002,420	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	sold off	-100	-1,000	-	-%
Apr 24, 2024	DekaBank Deutsche Girozentrale	unchanged	-	-159,000	462,000	-%
Apr 24, 2024	Simplicity Wealth,LLC	new	-	214,070	214,070	-%
Apr 23, 2024	FISHMAN JAY A LTD/MI	added	71.43	51,960	190,560	0.02%
Apr 23, 2024	AMALGAMATED BANK	reduced	-59.62	-27,000	13,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	-35,061	255,222	-%
Apr 18, 2024	Integrity Wealth Solutions LLC	unchanged	-	-65,070	263,600	0.17%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	90.28	85,794	248,887	0.01%

Are Funds Buying or Selling TNGX?

Are funds buying TNGX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TNGX

No. of Funds

Unveiling Tango Therapeutics, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 08, 2024	southpoint capital advisors lp	4.9%	5,276,699	SC 13G/A
Feb 14, 2024	southpoint capital advisors lp	5.2%	5,276,699	SC 13G/A
Feb 13, 2024	gilead sciences, inc.	-	0	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Oct 18, 2023	bctg holdings, llc	6.9%	6,988,450	SC 13D/A
Oct 16, 2023	ecor1 capital, llc	13.1%	13,330,736	SC 13G/A
Sep 21, 2023	ecor1 capital, llc	7.7%	7,827,636	SC 13G
Sep 11, 2023	fmr llc	-	0	SC 13G/A
Aug 21, 2023	nextech crossover i gp s.a r.l.	5.4%	5,533,980	SC 13G
Aug 16, 2023	bctg holdings, llc	6.9%	6,988,450	SC 13D/A

Recent SEC filings of Tango Therapeutics, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 17, 2024	PRE 14A	PRE 14A
Apr 08, 2024	SC 13G/A	Major Ownership Report
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Mar 18, 2024	S-8	Employee Benefits Plan
Feb 21, 2024	144	Notice of Insider Sale Intent
Feb 21, 2024	4	Insider Trading
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 09, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Tango Therapeutics, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.2B	6.8B	-2.42%	-17.04%	-8.75	6.02	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.0B	1.8B	-7.18%	-26.90%	-41	9.87	76.23%	61.08%
BMRN	15.3B	2.4B	-8.70%	-12.49%	91.05	6.31	15.42%	18.43%
INCY	11.6B	3.7B	-9.54%	-29.84%	19.41	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-14.77%	-39.78%	-11.37	15.16	425.83%	18.94%
BBIO	4.4B	-	-19.35%	75.41%	-6.7	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-9.32%	0.89%	-14.22	12.57	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.24%	-18.54%	-44.9	3.79	40.45%	71.62%
ARWR	2.7B	240.7M	-22.93%	-36.73%	-9.23	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.8B	398.2M	-8.48%	-5.52%	24.58	4.41	85.90%	-14.05%
NVAX	569.6M	983.7M	-16.08%	-46.16%	-1.05	0.58	-50.36%	17.16%
CRBP	361.2M	881.7K	-3.23%	346.43%	-8.1	466.16	-77.61%	-5.33%
INO	247.0M	4.9M	-18.88%	12.93%	-1.83	50.76	-54.97%	51.71%
IBIO	6.1M	2.1M	-47.62%	62.96%	-0.22	2.14	-13.45%	66.37%

Tango Therapeutics, Inc. News

Latest updates

Tango Therapeutics, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q2
Revenue	-49.4%	5,431,000	10,732,000	14,598,000	5,766,000	6,411,000	6,920,000	5,771,000	5,758,000	5,716,000	6,787,000	18,153,000	6,386,000	271,000	5,064,000
Operating Expenses	11.2%	40,444,500	36,358,000	37,845,000	36,052,000	36,978,000	36,843,000	30,973,000	31,137,000	27,700,000	26,356,000	22,709,000	18,467,000	18,079,000	13,507,000
S&GA Expenses	-1.1%	9,105,500	9,209,000	9,174,000	8,013,000	7,887,000	8,099,000	7,232,000	6,807,000	6,066,000	4,433,000	3,630,000	3,467,000	303,433	2,378,000
R&D Expenses	15.4%	31,339,000	27,149,000	28,671,000	28,039,000	29,091,000	28,744,000	23,741,000	24,330,000	21,634,000	21,923,000	19,079,000	15,000,000	15,063,000	11,129,000
EBITDA Margin	-2.6%	-2.56	-2.50	-2.91	-4.18	-4.23	-4.08	-3.73	-1.91	-1.53	-0.27	-0.53	-1.05	-6.68	-
Interest Expenses	19.4%	2,236,000	1,872,000	1,450,000	1,061,000	591,000	350,000	297,000	218,000	196,000	91,000	104,000	104,000	-	-
Income Taxes	-43.5%	13,000	23,000	64,000	-	51,000	-	3,000	-	177,000	62,000	-21,000	74,000	3,432	-
Earnings Before Taxes	-38.1%	-30,716,000	-22,240,000	-20,646,000	-	-29,009,000	-29,050,000	-24,855,000	-25,208,000	-21,869,000	-19,528,000	-4,514,000	-12,032,000	26,685,818	-8,392,000
EBT Margin	-4.4%	-2.81	-2.69	-3.07	-4.35	-4.35	-4.18	-3.81	-1.95	-1.56	-0.30	-0.56	-1.09	-6.79	-
Net Income	-38.2%	-30,763,000	-22,263,000	-20,710,000	-28,008,000	-29,060,000	-29,050,000	-24,858,000	-25,208,000	-22,046,000	-19,590,000	-4,493,000	-12,106,000	-8,864,000	-8,392,000
Net Income Margin	-4.4%	-2.79	-2.67	-3.17	-4.46	-4.35	-4.19	-3.82	-1.96	-1.57	-1.43	-1.75	-2.99	-6.79	-
Free Cashflow	11.1%	-27,693,000	-31,151,000	-25,137,000	-35,527,000	-29,307,000	-22,890,000	-33,349,000	-31,226,000	-17,598,000	-22,268,000	-7,720,000	-13,778,000	-9,606,071	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-6.0%	403	428	379	404	436	464	448	472	500	530	217	168	207	168	56.00
Current Assets	-6.6%	347	371	321	343	375	402	436	461	492	516	202	1.00	194	2.00	42.00
Cash Equivalents	13.4%	66.00	59.00	66.00	57.00	60.00	100	105	100	143	205	51.00	1.00	28.00	2.00	23.00
Net PPE	-3.4%	10.00	10.00	11.00	11.00	11.00	11.00	8.00	7.00	5.00	5.00	4.00	-	4.00	-	3.00
Liabilities	-1.4%	149	152	166	177	187	191	150	151	155	165	162	166	169	6.00	48.00
Current Liabilities	5.8%	46.00	43.00	54.00	54.00	56.00	51.00	45.00	39.00	41.00	42.00	37.00	0.00	41.00	0.00	26.00
Shareholder's Equity	-8.5%	253	277	213	227	249	273	299	320	345	365	55.00	58.00	39.00	47.00	8.00
Retained Earnings	-9.0%	-371	-340	-318	-297	-269	-240	-211	-186	-161	-139	-119	-0.36	-103	-0.05	-51.13
Additional Paid-In Capital	1.0%	624	618	533	527	523	518	514	510	507	505	8.00	5.00	142	5.00	3.00
Shares Outstanding	0.3%	102	102	88.00	88.00	88.00	88.00	88.00	88.00	88.00	53.00	49.00	42.00	40.00	29.00	-
Float	-	-	-	177	-	-	-	302	-	-	-	190	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2019Q4
Cashflow From Operations	11.8%	-27,467	-31,135	-24,473	-34,907	-28,266	-19,611	-31,538	-29,665	-16,902	-21,494	-7,518	-13,613	-9,150	-89.28	-	-
Share Based Compensation	0.4%	4,879	4,860	5,121	4,219	3,785	3,815	3,425	3,205	2,257	3,430	1,196	950	531	418	-	-
Cashflow From Investing	159.7%	33,852	-56,664	32,687	31,551	-12,605	15,228	35,493	-11,717	-45,207	-152,214	-6,625	20,612	-29,605	-166,750	-	-
Cashflow From Financing	-98.2%	1,467	80,280	586	73.00	527	113	718	257	-120	327,780	-746	30,411	-30.50	168,392	-	-

TNGX Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Collaboration revenue	$ 36,527	$ 24,860
Operating expenses:
Research and development	115,198	105,906
General and administrative	35,502	30,025
Total operating expenses	150,700	135,931
Loss from operations	(114,173)	(111,071)
Other income :
Interest income	6,619	1,456
Other income , net	5,944	1,493
Total other income, net	12,563	2,949
Loss before income taxes	(101,610)	(108,122)
Provision for income taxes	(134)	(54)
Net loss	$ (101,744)	$ (108,176)
Net loss per common share - basic	$ (1.08)	$ (1.23)
Net loss per common share - diluted	$ (1.08)	$ (1.23)
Weighted-average common stock outstanding - basic	94,572,448	87,820,037
Weighted-average common stock outstanding - diluted	94,572,448	87,820,037
Net Income (Loss)	$ (101,744)	$ (108,176)
Other comprehensive income (loss):
Unrealized gain (loss) on marketable securities	3,891	(2,940)
Comprehensive loss	(97,853)	(111,116)
Collaboration Revenue [Member]
Collaboration revenue	31,527	$ 24,860
License Revenue [Member]
Collaboration revenue	$ 5,000

TNGX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 66,385	$ 59,968
Marketable securities	270,500	306,165
Accounts receivable		2,000
Restricted cash	856	567
Prepaid expenses and other current assets	8,797	6,572
Total current assets	346,538	375,272
Property and equipment, net	9,908	10,884
Operating lease right-of-use assets	43,508	46,886
Restricted cash, net of current portion	2,567	3,423
Other assets	46	5
Total assets	402,567	436,470
Current liabilities:
Accounts payable	2,785	4,453
Accrued expenses and other current liabilities	15,401	17,495
Operating lease liabilities	2,082	1,770
Deferred revenue	25,670	31,792
Income tax payable		35
Total current liabilities	45,938	55,545
Operating lease liabilities, net of current portion	36,838	39,361
Deferred revenue, net of current portion	66,683	92,088
Total liabilities	149,459	186,994
Commitments and contingencies (Note 8)
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and 2022, respectively
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2023 and December 31, 2022, respectively; 102,202,759 and 88,179,374 shares issued and outstanding as of December 31, 2023 and 2022, respectively	102	88
Additional paid-in capital	624,076	522,605
Accumulated other comprehensive income (loss)	186	(3,705)
Accumulated deficit	(371,256)	(269,512)
Total stockholders' equity	253,108	249,476
Total liabilities and stockholders' equity	$ 402,567	$ 436,470

About Tango Therapeutics, Inc.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is headquartered in Boston, Massachusetts.

CEO	Dr. Barbara L. Weber M.D.
WEBSITE	tangotx.com
INDUSTRY	Biotechnology
EMPLOYEES	110

Tango Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Tango Therapeutics, Inc.? What does TNGX stand for in stocks?

TNGX is the stock ticker symbol of Tango Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tango Therapeutics, Inc. (TNGX)?

As of Fri Apr 26 2024, market cap of Tango Therapeutics, Inc. is 793.98 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TNGX stock?

You can check TNGX's fair value in chart for subscribers.

What is the fair value of TNGX stock?

You can check TNGX's fair value in chart for subscribers. The fair value of Tango Therapeutics, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tango Therapeutics, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TNGX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tango Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TNGX is over valued or under valued. Whether Tango Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Tango Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TNGX.

What is Tango Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, TNGX's PE ratio (Price to Earnings) is -7.8 and Price to Sales (PS) ratio is 21.74. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TNGX PE ratio will change depending on the future growth rate expectations of investors.